COVID-19 Screening Program
NCT05216627 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 61
Last updated 2024-07-31
Summary
In view of the recent COVID surge and difficulties in obtaining testing, we aim to increase Point of Care (POC) testing, whereby University of Pennsylvania (Penn) faculty, staff, and trainees who are working in person at Perelman School of Medicine (PSOM) laboratories can self-test. The purpose of this study is to evaluate the implementation of this POC testing program. We will not be collecting any samples as part of this study. This will ensure that individuals can rapidly identify if they have COVID-19 while balancing use, acceptability, appropriateness, and feasibility. We will start with a pilot phase whereby we will evaluate the implementation of a POC version of COVID-19 screening program that will coordinate several existing systems at the University of Pennsylvania including voluntary, self-administered saliva-based viral testing. We will pilot this program to a small cohort of PSOM labs and then test implementation of the self-testing of the POC version of COVID-19 screening across all PSOM labs for those who wish to participate. All results will be self-reported and will not be used to validate any tests or support any future approval from the FDA. No data from this study will go into the participants' Electronic Medical Record (EMR).
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Self-administered saliva-based viral testing
Participants will be instructed on how to inactivate the virus and bring their sample to their laboratory's central PCR machine, where they will take an assay test. They will be instructed to collect saliva into a 1.5 milliliter (mL) collection tube containing inactivation buffer (TCEP and EDTA) using a small funnel and inactivate at 95°C for 10 minutes. Participants will then transfer 6ul of saliva into 2 PCR tubes containing amplification master mix and primers, put tubes in a heat block or PCR machine at 65°C for 45 minutes and assess fluorescence using a simple battery-powered fluorescence viewer. Once they assess their sample, they will be instructed to dispose of the saliva sample safely and in accordance with best laboratory practices. No saliva samples will be collected by the research team at any time as part of this study.
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Rinad Beidas, PhD · University of Pennsylvania
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-02-07
- Primary Completion
- 2022-07-01
- Completion
- 2022-07-01
Countries
- United States
Study Locations
More Related Trials
-
Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)
NCT04328961 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Convalescent Plasma in Outpatients With COVID-19
NCT04355767 ·Status: COMPLETED ·Phase: PHASE3
-
Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients
NCT04523181 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19
NCT05305547 ·Status: COMPLETED ·Phase: PHASE3
-
COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.
NCT04397757 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection
NCT05897541 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Evaluation of Paxlovid for COVID-19: a Real-world Case-control Study
NCT05532852 ·Status: UNKNOWN ·Phase: NA
-
Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use
NCT06734741 ·Status: COMPLETED
-
Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population
NCT04561102 ·Status: COMPLETED
-
IMM-BCP-01 in Mild to Moderate COVID-19
NCT05429021 ·Status: TERMINATED ·Phase: PHASE1
-
PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)
NCT04842331 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose
NCT05392075 ·Status: COMPLETED
-
COVID-19 Self-testing Study
NCT05701878 ·Status: COMPLETED ·Phase: NA
-
Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)
NCT05787444 ·Status: UNKNOWN
-
Anti-inflammatory Drug Algorithm for COVID-19 Home Treatment
NCT05249790 ·Status: WITHDRAWN ·Phase: PHASE3
-
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel to Support Home Use
NCT06124638 ·Status: COMPLETED ·Phase: NA
-
RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms
NCT05965726 ·Status: COMPLETED ·Phase: PHASE2
-
A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms
NCT05212532 ·Status: UNKNOWN ·Phase: PHASE1
-
Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19
NCT04405570 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa
NCT05459532 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19
NCT04532931 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of Rapid Flu Testing in BMC ED
NCT02979730 ·Status: COMPLETED ·Phase: NA
-
COVID-19 Saliva Test Research Study
NCT04531501 ·Status: COMPLETED
-
Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure
NCT04705597 ·Status: TERMINATED ·Phase: PHASE2
-
Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients
NCT05077969 ·Status: TERMINATED ·Phase: PHASE2